A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects.

Trial Profile

A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Maraviroc (Primary) ; Efavirenz; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms MERIT; MERIT-ES
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 27 Oct 2017 Results of post-hoc analysis (n=895) assessing the effect of maraviroc versus efavirenz on the CD4/CD8 ratio dynamics, presented at the 16th European AIDS Conference.
    • 09 Oct 2017 Results (n=721) of post-hoc analysis of Merit study (NCT00098293, NCT03178084), published in the Antimicrobial Agents and Chemotherapy Journal.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top